Secondary negative symptoms — A review of mechanisms, assessment and treatment
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The empirical status of cognitive-behavioral therapy: A review of meta-analyses
Butler, A. C., Chapman, J. E., Forman, E. M., & Beck, A. T. (2006) · Clinical Psychology Review · doi:10.1016/j.cpr.2005.07.003 · Cited by 3,215
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Berridge, K. C., & Robinson, T. E. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00233-9 · Cited by 1,869
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121
Wykes, T., Steel, C., Everitt, B., & Tarrier, N. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm114 · Cited by 1,029
Substantia nigra/ventral tegmental reward prediction error disruption in psychosis
Murray, G. K., Corlett, P. R., Clark, L., Pessiglione, M., Blackwell, A. D., Honey, G., Jones, P. B., Bullmore, E. T., Robbins, T. W., & Fletcher, P. C. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002058 · Cited by 532
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp130 · Cited by 499
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Groenewold, N. A., Opmeer, E. M., de Jonge, P., Aleman, A., & Costafreda, S. G. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.11.015 · Cited by 417
Self-citation
Cited by
Negative symptoms of schizophrenia: new developments and unanswered research questions
Galderisi, S., Mucci, A., Buchanan, R. W., & Arango, C. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30050-6 · Cited by 555
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Edwards, C. J., Garety, P., & Hardy, A. (2019) · Psychological Medicine · doi:10.1017/s0033291719002381 · Cited by 54
Antipsychotic drugs: challenges and future directions
Howes, O. H., & Kaar, S. J. (2018) · World Psychiatry · doi:10.1002/wps.20522 · Cited by 24
Ebrahimi, A., Poursharifi, H., Dolatshahi, B., Rezaee, O., Hassanabadi, H. R., & Naeem, F. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707291 · Cited by 21
“Similarly, side effects of antipsychotic drugs might lead to secondary negative symptoms or at least exacerbate negative symptoms (3, 11, 12).”
BackgroundLyngstad, S. H., Gardsjord, E. S., Engen, M. J., Haatveit, B., Ihler, H. M., Wedervang-Resell, K., Simonsen, C., Melle, I., & Færden, A. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01112-3 · Cited by 16
Lyngstad, S. H., Gardsjord, E. S., Simonsen, C., Engen, M. J., Romm, K. L., Melle, I., & Færden, A. (2018) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2018.07.015 · Cited by 12
Metadata
- Authors
- Kirschner, M., Aleman, A., & Kaiser, S.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 186
- Pages
- 29-38
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2401721725
- Cited by
- 215
- References
- 27
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.